A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer (Q46679640)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2005

Language	Label	Description	Also known as
English	A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer	scientific article published in October 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

object named as

Jaffer A Ajani

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

author name string

Chris Takimoto

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Carlos R Becerra

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Alejandro Silva

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Luis Baez

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Allen Cohn

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Pierre Major

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Makio Kamida

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Kevie Feit

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Robert De Jager

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

23

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

479-484

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

https://scigraph.springernature.com/pub.10.1007/s10637-005-2907-z

0 references

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2907-Z

21 January 2018

Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-2907-Z

21 January 2018

Antitumour activity of DX-8951f: a new camptothecin derivative.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The current status of camptothecin analogues as antitumor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DX-8951f: summary of phase I clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of topotecan administered five times daily in patients with advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant treatment in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133799

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-2907-Z

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

release_eva5m3a4wbdkdmimoftn4rpsyy

1 reference

https://api.fatcat.wiki/v0/release/eva5m3a4wbdkdmimoftn4rpsyy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133799

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46679640&oldid=2144497258"